Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
gptkb:Elexacaftor
gptkb:Ivacaftor |
| gptkbp:alsoKnownAs |
gptkb:Tezacaftor
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:R07AX31
|
| gptkbp:CASNumber |
1152311-62-0
|
| gptkbp:chemicalFormula |
C26H28F3N3O3
|
| gptkbp:developedBy |
gptkb:Vertex_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
VX-661
|
| gptkbp:indication |
treatment of cystic fibrosis with specific CFTR mutations
|
| gptkbp:marketedAs |
gptkb:Symdeko
gptkb:Trikafta |
| gptkbp:mechanismOfAction |
CFTR modulator
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:target |
gptkb:CFTR_protein
|
| gptkbp:usedFor |
cystic fibrosis
|
| gptkbp:bfsParent |
gptkb:tezacaftor
|
| gptkbp:bfsLayer |
7
|